DOTATATE PET Scan for Meningioma
(DOTATATE-RT Trial)
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment DOTATATE-PET for meningioma?
How does the DOTATATE PET scan treatment differ from other treatments for meningioma?
The DOTATATE PET scan treatment is unique because it uses a special imaging technique to detect meningioma tissue by targeting somatostatin receptors, which are often present in these tumors. This method is more sensitive than traditional MRI in identifying the spread of the tumor into the bone, helping in better diagnosis and treatment planning.23567
What is the purpose of this trial?
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Eligibility Criteria
This trial is for individuals with meningioma, a type of brain tumor. Participants should be candidates for radiation therapy and can have any grade of meningioma. Specific eligibility criteria are not provided here, but typically include age, health status, and prior treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
DOTATATE-PET Scan
Participants undergo a DOTATATE-PET scan for radiation planning
Radiation Planning and Treatment
Radiation therapy contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Follow-up
Participants are monitored for safety and effectiveness after radiation treatment
Treatment Details
Interventions
- DOTATATE-PET
Find a Clinic Near You
Who Is Running the Clinical Trial?
British Columbia Cancer Agency
Lead Sponsor